GlassScriptPhysician profile
David Wade Redick
NPI 1770078859
$3,592.41
in general payments reported to CMS, 2019-2025
12 companies · $302 in 2025
The $302 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $218 · 2021: $306 · 2022: $447 · 2023: $141 · 2024: $1,815 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,313 · Food and Beverage: $853 · Travel and Lodging: $93.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,312.50 |
| Food and Beverage | $853.27 |
| Travel and Lodging | $93.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,548.39 | 2024-2025 | |
| Alcon Vision LLC | $637.73 | 2019-2024 | Constellation |
| Novartis Pharmaceuticals Corporation | $373.35 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $261.97 | 2024-2025 | Eylea Hd |
| Dutch Ophthalmic, USA | $183.33 | 2021-2022 | |
| Eyepoint US, INC. | $175.59 | 2022 | |
| Glaukos Corporation | $147.82 | 2021 | |
| Alimera Sciences, INC. | $131.21 | 2024 | Iluvien, Yutiq |
| Allergan, INC. | $91.87 | 2020 | |
| Genentech USA, INC. | $16.24 | 2025 | Vabysmo |
| Harrow Eye, LLC | $15.79 | 2025 | Iheezo |
| Oculus Surgical INC. | $9.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Redick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.